Esmo Open
ESMO Presidential Symposium: Final overall survival analysis from the FLAURA trial
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:06:31
- More information
Informações:
Synopsis
Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis. The phase III trial Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA) showed a significant increase in progression free survival. In the now available finale survival analysis also the overall survival showed a statistical significant increase. Expert: Suresh S. Ramalingam, Winship Cancer Institute of Emory University, Atlanta, GA
